Trial reportNature communications2022
The Neo-PLANET phase II trial of neoadjuvant camrelizumab plus concurrent chemoradiotherapy in locally advanced adenocarcinoma of stomach or gastroesophageal junction.
Registry-linked trialOpen access · goldAbstract readClinical Trial, Phase II
In one paragraph
Trial report in Nature communications, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03631615 (A Phase II Study of Neoadjuvant Chemoradiation Plus PD-1 Antibody), which is not on this map. Cited by 66 papers, 8 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
66citing papers in PubMed, 8 pooled it
11.4field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Phase II Study of Neoadjuvant Chemoradiation Plus PD-1 Antibody(SHR-1210) in the Locally Advanced Proximal Stomach Adenocarcinoma (Neo-PLANET)
Who cites it
66 citing papers in PubMed, 8 syntheses or guidelines pooled it, 80 citations in OpenAlex.
- Neoadjuvant Therapy for Locally Advanced Gastric/Gastroesophageal Junction Adenocarcinoma: Current Status, Challenges, and Future Perspectives.Cancer medicine · 2026Pooled it
- Updated pan-tumor guidelines for neoadjuvant scoring of pathologic response: a joint SITC and INMC effort.Annals of oncology : official journal of the European Society for Medical Oncology · 2026Guideline
- Efficacy and safety of neoadjuvant chemoradiotherapy combined with immunotherapy for locally advanced esophagogastric junction or gastric cancer: a systematic review and meta analysis.Frontiers in immunology · 2026Pooled it
- Impact of immune checkpoint inhibitors as neoadjuvant/perioperative therapy for locally advanced resectable gastric/gastroesophageal junction adenocarcinoma: a systematic review and meta-analysis.Frontiers in immunology · 2026Pooled it
- Neoadjuvant immunotherapy improves outcomes for resectable gastroesophageal junction cancer: A systematic review and meta-analysis.Cancer medicine · 2024Pooled it
- The efficacy of neoadjuvant immunotherapy in gastric cancer, adenocarcinoma of the esophagogastric junction, and esophageal cancer: a meta-analysis.Frontiers in oncology · 2024Pooled it
- Evaluation of neoadjuvant immunotherapy in resectable gastric/gastroesophageal junction tumors: a meta-analysis and systematic review.Frontiers in immunology · 2024Pooled it
- Comparison of neoadjuvant immunotherapy versus routine neoadjuvant therapy for patients with locally advanced esophageal cancer: A systematic review and meta-analysis.Frontiers in immunology · 2023Pooled it
- Neoadjuvant immunochemotherapy plus thymalfasin in locally advanced gastric cancer: a prospective clinical trial.BMC medicine · 2026Trial
- Three-Year Follow-Up of Neoadjuvant Tislelizumab with Chemotherapy in Locally Advanced Gastric and Gastroesophageal Junction Adenocarcinoma: Revealing Cancer-Associated Fibroblast Heterogeneity Corresponding to PD-1 Blockade Efficacy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Trial
- Preoperative Chemoradiotherapy versus Chemotherapy for Locally Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma: A Phase III Randomized Controlled Trial from China.Cancer communications (London, England) · 2026Trial
- Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy for locally advanced rectal cancer: 3-year survival from a phase 2 study.BMC medicine · 2025Trial
- Two-Year Outcomes and Biomarker Analysis of Locally Advanced Gastric and Gastroesophageal Junction Adenocarcinoma After Neoadjuvant Chemotherapy and Immunotherapy from the Phase II WuhanUHGI001 Trial.Annals of surgical oncology · 2024Trial
- Comprehensive multi-omics analysis of resectable locally advanced gastric cancer: Assessing response to neoadjuvant camrelizumab and chemotherapy in a single-center, open-label, single-arm phase II trial.Clinical and translational medicine · 2024Trial
- A prospective phase II clinical trial of total neoadjuvant therapy for locally advanced gastric cancer and gastroesophageal junction adenocarcinoma.Scientific reports · 2024Trial
- Neoadjuvant sintilimab in combination with concurrent chemoradiotherapy for locally advanced gastric or gastroesophageal junction adenocarcinoma: a single-arm phase 2 trial.Nature communications · 2023Trial
- Tertiary lymphoid structures guided opportunities and challenges for immunotherapy in early gastroesophageal junction cancer and low rectal cancer.Human vaccines & immunotherapeutics · 2026Review
- Transforming perioperative treatment of gastro-oesophageal adenocarcinoma: triumphs, setbacks and future horizons.Nature reviews. Clinical oncology · 2026Review
- Development and validation of a collagen score-based prediction model for neoadjuvant chemoimmunotherapy efficacy in locally advanced esophageal squamous cell carcinoma.Journal of thoracic disease · 2026Article
- Synergizing Radiotherapy and Immune Checkpoint Inhibitors in Malignant Solid Tumours: Mechanistic Insights and Translational Frontiers.Expert reviews in molecular medicine · 2026Review
6 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors at 4 institutions in 2 countries.
Zhaoqing Tang *Department of General Surgery, Zhongshan Hospital, Fudan University, Shanghai, China.ORCID 0000-0001-5286-6330
Yan Wang *Department of Medical Oncology, Zhongshan Hospital, Fudan University, Shanghai, China.
Dan Liu *Department of General Surgery, Zhongshan Hospital, Fudan University, Shanghai, China.
Xuefei Wang *Department of General Surgery, Zhongshan Hospital, Fudan University, Shanghai, China. wang.xuefei@zs-hospital.sh.cn.ORCID 0000-0002-2645-0953
Chen XuDepartment of Pathology, Zhongshan Hospital, Fudan University, Shanghai, China.ORCID 0000-0002-0858-945X
Yiyi YuDepartment of Medical Oncology, Zhongshan Hospital, Fudan University, Shanghai, China.
Yuehong CuiDepartment of Medical Oncology, Zhongshan Hospital, Fudan University, Shanghai, China.
Cheng TangDepartment of Medical Oncology, Zhongshan Hospital, Fudan University, Shanghai, China.
Qian LiDepartment of Medical Oncology, Zhongshan Hospital, Fudan University, Shanghai, China.
Jing SunDepartment of Radiotherapy, Zhongshan Hospital, Fudan University, Shanghai, China.
Qian ZhangDepartment of Radiotherapy, Zhongshan Hospital, Fudan University, Shanghai, China.
Yuan JiDepartment of Pathology, Zhongshan Hospital, Fudan University, Shanghai, China.ORCID 0000-0002-2631-9082
Guifen MaDepartment of Radiotherapy, Zhongshan Hospital, Fudan University, Shanghai, China.
Haojie LiDepartment of General Surgery, Zhongshan Hospital, Fudan University, Shanghai, China.
Zhenbin ShenDepartment of General Surgery, Zhongshan Hospital, Fudan University, Shanghai, China.
Kuntang ShenDepartment of General Surgery, Zhongshan Hospital, Fudan University, Shanghai, China.ORCID 0000-0002-9600-6508
Rongrong ZhengDepartment of Medical Affairs, Jiangsu Hengrui Pharmaceuticals Co., Ltd., Shanghai, China.
Zhiguo HouDepartment of Medical Affairs, Jiangsu Hengrui Pharmaceuticals Co., Ltd., Shanghai, China.
Tianshu LiuDepartment of Medical Oncology, Zhongshan Hospital, Fudan University, Shanghai, China. liu.tianshu@zs-hospital.sh.cn.ORCID 0000-0002-8604-6311
Jiping WangDivision of Surgical Oncology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA. jwang39@partners.org.
Yihong SunDepartment of General Surgery, Zhongshan Hospital, Fudan University, Shanghai, China. sun.yihong@zs-hospital.sh.cn.ORCID 0000-0003-3779-1953
Sun Yat-sen University · CNFudan University · CNJiangsu Hengrui Medicine (China) · CNBrigham and Women's Hospital · US
Funding
No grant is acknowledged in the PubMed record.
Abstract
The synergistic effect of neoadjuvant immunotherapy and chemoradiotherapy in gastric adenocarcinoma is unclear. This phase II trial (NCT03631615) investigated this neoadjuvant combination in locally advanced adenocarcinoma of stomach or gastroesophageal junction. Thirty-six patients received capecitabine 850 mg/m
Indexed as
AdenocarcinomaRectal NeoplasmsStomach NeoplasmsAntibodies, Monoclonal, HumanizedAntineoplastic Combined Chemotherapy ProtocolsCapecitabineChemoradiotherapyEsophagogastric JunctionHumansNeoadjuvant TherapyPlanetsAntibodies, Monoclonal, HumanizedcamrelizumabCapecitabine
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
NCT03631615ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.